Weekly Digest – May 2026 Weekly Digest – May 2026 11 May 2026: HS-20093 granted Breakthrough Therapy Designation by NMPA for Esophageal cancer treatment Hansoh Pharma has secured another important regulatory milestone after China’s NMPA granted Breakthrough Therapy Designation to […]
Weekly Digest – May 2026 Weekly Digest – May 2026 11 May 2026: SYS6010 has received another BTD in China for the treatment of patients with locally advanced or metastatic ESCC CSPC Pharmaceutical has secured another Breakthrough Therapy Designation from […]
Weekly Digest – May 2026 Weekly Digest – May 2026 12 May 2026: Emiltatug Ledadotin has been granted Breakthrough Therapy Designation by the U.S. FDA for the treatment of Adenoid cystic carcinoma Servier has secured U.S. FDA Breakthrough Therapy Designation […]
Weekly Digest – May 2026 Weekly Digest – May 2026 11 May 2026: Zai Lab announced that Zocilurtatug Pelitecan has received U.S. FDA FTD for the treatment of extrapulmonary Neuroendocrine carcinomas Zai Lab has received U.S. FDA Fast Track Designation […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: InnoCare Pharma’s independently developed CDH17-targeted ADC innovative drug ICP B208 has been approved for clinical trials InnoCare Pharma has expanded its ADC pipeline after receiving National Medical […]
Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: ArriVent announces IND clearance for novel tetravalent MUC16/NaPi2b targeting ADC ARR-002 with initial focus in Ovarian and Endometrial cancers ArriVent BioPharma has received IND clearance for ARR-002, […]
Weekly Digest – May 2026 Weekly Digest – May 2026 29 April 2026: The NMPA has granted BTD for B7-H3-targeted ADC HS-20093 for castration-resistant prostate cancer Hansoh Pharmaceutical announced that China’s National Medical Products Administration has granted Breakthrough Therapy designation […]
Weekly Digest – May 2026 Weekly Digest – May 2026 30 April 2026: Alphamab Oncology announces IND application for TROP2/HER3 bispecific ADC JSKN016SC officially accepted by CDE Alphamab Oncology announced that the IND application for its TROP2/HER3 bispecific antibody–drug conjugate […]
Weekly Digest – May 2026 Weekly Digest – May 2026 28 April 2026: Taiho Pharmaceutical and Araris Biotech AG advance ADC ARC-02 into phase 1 clinical development Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech announced that the U.S. FDA has […]
Weekly Digest – May 2026 Weekly Digest – May 2026 29 April 2026: SYS6051 obtains clinical trial approval in the U.S. CSPC Pharmaceutical Group announced that the U.S. FDA has approved the Investigational New Drug application for its antibody drug […]
